Ibrutinib has been selected for Medicare price negotiation under the Inflation Reduction Act. The authors summarize the House Oversight Committee investigation to be considered by CMS during the price negotiation process.
Kenneth R. Carson, MD
Advertisement
Articles by Kenneth R. Carson, MD
Use of granulocyte colony-stimulating factor plus plerixafor for stem cell mobilization is cost-effective in pretreated patients with non-Hodgkin lymphoma.
Advertisement
Latest Updated Articles
Adjusting Starting Points for Initial Price Offers: The Example of IbrutinibPublished: April 2nd 2024 | Updated:
- Economic Evaluation of Plerixafor for Stem Cell Mobilization
Published: January 19th 2012 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Trump Administration Flags Potential Link Between Prenatal Acetaminophen Use, Autism
2
Childhood Cancer Awareness Month Spotlights Barriers That Persist in Care
3
Nicotinamide Reduces New Skin Cancer Risk in Large Veteran Study
4
More Effective CKD Strategy Could Have Health, Societal Benefits
5
